Personalized mRNA Vaccine Shows Significant Reduction in Melanoma Recurrence
Researchers at Moderna and Merck have developed a personalized mRNA cancer vaccine that significantly reduces the risk of recurrence in high-risk melanoma patients. The treatment uses patient-specific genetic data to…